Welcome to our dedicated page for BIOC news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on BIOC stock.
Biocept, Inc. (BIOC) pioneers molecular diagnostics for cancer management through its proprietary Target Selector™ technology. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s advancements in liquid biopsy solutions and oncology research.
Access real-time announcements including financial results, strategic partnerships, and clinical validation studies. Our curated collection ensures efficient tracking of Biocept’s progress in developing non-invasive diagnostic tools that inform treatment decisions and improve patient care pathways.
Key updates cover regulatory milestones, technology enhancements, and collaborations with biopharmaceutical partners. Bookmark this page for direct access to primary source materials, including earnings calls analysis and product launch details, all organized for informed decision-making.
Biocept (Nasdaq: BIOC) has appointed Linda Rubinstein and Antonino Morales to its Board of Directors, expanding the board from seven to nine members. Samuel D. Riccitelli has been named Chairman, succeeding David Hale and interim Chair M. Faye Wilson, who remain Directors. Rubinstein and Morales bring extensive financial and leadership expertise, enhancing Biocept's focus on strategic growth in oncology diagnostics. Riccitelli emphasized the board's commitment to advancing Biocept's initiatives, particularly its new CNSide™ assay aimed at improving cancer patient outcomes.
Biocept, Inc (Nasdaq: BIOC) announces that President and CEO Michael Nall will attend two upcoming investment conferences. The first is the Brookline Capital Markets Newport Symposium on July 26, focusing on transformative biotech, featuring group discussions and one-on-one meetings. The second is the A.G.P.’s Virtual MedTech Summer Conference on July 29, also including one-on-one investor meetings. Biocept specializes in molecular diagnostic assays aimed at enhancing cancer treatment and monitoring.
Biocept (NASDAQ: BIOC) has secured a South Korean Patent for its innovative Primer-Switch technology, aimed at detecting rare mutations in circulating tumor DNA (ctDNA). This patent (No. 2252447) is the fourth for this technology, crucial in identifying cancer biomarkers in various bodily fluids. The Primer-Switch enhances PCR performance, widely used for both research and clinical diagnostics. With over 70 patents globally, Biocept continues to develop its molecular diagnostic capabilities, improving physician decision-making in cancer treatment.
Biocept (Nasdaq: BIOC) announced its addition to the Russell Microcap Index effective June 28, 2021. This inclusion will raise awareness of the company in the investment community, according to CEO Michael Nall. Biocept is commercializing its proprietary CNSide™ assay for diagnosing tumors that have metastasized to the central nervous system. Membership in the Russell Microcap Index lasts for one year and is important as it serves as a benchmark for smaller growth stocks, influencing a significant amount of investment assets.
Biocept, Inc. (Nasdaq: BIOC) announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide its Target Selector NGS-based liquid biopsy assay for lung cancer testing. This assay, designed for patients with advanced non-small cell lung cancer, enables less invasive genomic profiling and monitoring of treatment effectiveness. Expected to launch in Q4 2021, the service will be accessible through Quest's extensive patient service centers across the U.S. This partnership aims to enhance patient care and expand Biocept’s market reach in oncology diagnostics.
Biocept, Inc. (Nasdaq: BIOC) has processed over 420,000 SARS-CoV-2 samples since June 2020, utilizing its RT-PCR technology at its San Diego laboratory. The company plans to enhance its offerings with COVID-19 and seasonal influenza testing starting Q3. Anticipating increased testing demand as colleges resume in-person classes, Biocept has been selected to support COVID-19 testing for all 116 California community colleges. Financially, the company reported revenue growth from COVID-19 testing while reducing related expenses through self-production of sample collection kits.
Biocept (Nasdaq: BIOC) has partnered with CLEARED4 to develop a system for managing COVID-19 testing requirements and results for its customers. This collaboration will utilize CLEARED4's health platform, enabling organizations to track testing protocols in real-time through a secure dashboard. Biocept has processed over 400,000 COVID-19 samples at its San Diego lab, with most results available within 48 hours. This initiative aims to support public health efforts and facilitate safer environments as businesses and educational institutions reopen.
Biocept, Inc. (Nasdaq: BIOC) announced that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021. The company aims to update investors on CNSide™, its new assay for diagnosing tumors that have metastasized to the central nervous system. With a full commercial launch underway, CNSide™ could benefit around 200,000 patients annually in the U.S. Registration for the presentation is available online, and a webcast will be accessible on the company’s website for 90 days after the event.
Biocept, Inc. (Nasdaq: BIOC) announced the grant of inducement stock options for 144,580 shares to eighteen new employees as of May 31, 2021. The options have an exercise price of $4.52 per share, based on the closing price on May 28, 2021. These non-qualified stock options have a ten-year term and will vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments for the next 36 months, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4).
Biocept, Inc. (Nasdaq: BIOC) reported a strong financial performance for Q1 2021, achieving revenues of $17.8 million, up from $1.4 million in Q1 2020, largely driven by COVID-19 RT-PCR testing. The company reported a net income of $2.6 million or $0.19 per diluted share. Biocept's CNSide assay, targeting metastatic cancer detection in cerebrospinal fluid, is now commercially launched and shows promising initial results. The company continues to expand its COVID-19 testing services, recently partnering with California community colleges to enhance campus safety.
